DEF 14A: Penumbra, Inc. Announces 2024 Annual Meeting of Stockholders

Penumbra, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 5, 2024, to elect directors, ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approve executive compensation on an advisory basis.

Summary

• Penumbra, Inc. will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 11:00 a.m. Pacific Daylight Time, at One Penumbra Place, Alameda, CA 94502.
• Stockholders of record as of April 12, 2024, are eligible to vote.
• The meeting will address the election of Class III directors, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
• The Board of Directors recommends voting for the election of all director nominees, for the ratification of PricewaterhouseCoopers LLP, and for the advisory approval of the compensation of the company's named executive officers.
• Stockholders can vote by proxy via telephone, internet, or mail, or in person at the Annual Meeting.
• The company's Board of Directors is divided into three classes, with Class III directors serving until the 2027 annual meeting.
• The Nominating and Corporate Governance Committee has renominated Adam Elsesser and Harpreet Grewal as Class III director nominees.
• The Board has determined that all director nominees and continuing directors, other than Adam Elsesser and Arani Bose, M.D., are independent directors.
• The Audit Committee has selected PricewaterhouseCoopers LLP (PwC) as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and dismissed Deloitte & Touche LLP (Deloitte).
• The Audit Committee recommended to the Board, and the Board approved, that the audited financial statements be included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for filing with the SEC.
• The company's executive compensation program includes base salary and long-term equity awards.
• The Board has adopted a Code of Business Conduct and Ethics that applies to all employees and directors.
• The Board has adopted a formal anti-hedging and anti-pledging policy for our employees (including our executive officers) and directors.
• The company's non-employee directors are expected to hold shares of the company's common stock with a dollar value equal to at least three times (3x) the non-employee director annual cash retainer.
• The company's non-employee director annual cash retainer is $54,000.
• The company's non-employee directors also receive an annual grant of RSUs in an amount equal to three and one-third times the non-employee director annual cash retainer of $54,000, divided by the adjusted closing price of Penumbra's common stock on the date of grant, rounded up or down to the nearest whole share.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company is performing well financially, but there are some risks and challenges mentioned.

Positives

• The Board recommends voting for the director nominees, ratifying PwC as the auditor, and approving executive compensation.
• The company has a Code of Business Conduct and Ethics and an anti-hedging and anti-pledging policy in place.
• The company's non-employee directors are expected to hold shares of the company's common stock with a dollar value equal to at least three times (3x) the non-employee director annual cash retainer, aligning their interests with shareholders.

Negatives

• Deloitte & Touche LLP (Deloitte) was dismissed as the Companys independent registered public accounting firm.

Risks

• The proxy statement mentions a settlement of litigation against Harpreet Grewal, a director nominee, related to SEC allegations from his previous role at Constant Contact, which could raise concerns for some investors.
• The company's future executive compensation may not be fully deductible due to limitations under Section 162(m) of the Code.

Future Outlook

The Compensation Committee will continue to review our executive compensation philosophy to determine whether any changes to our current philosophy are required to reward, incentivize, and retain our NEOs, or for other purposes.

Management Comments

• Throughout his tenure as our Chief Executive Officer, Mr. Elsesser has expressed a preference to the Compensation Committee that his cash compensation be modest so we could invest in other areas of the business.
• We are confident that our streamlined compensation program aligns with our culture of cooperation and that it incentivizes our NEOs to work for the overall long-term good of the Company.

Industry Context

The document provides information on Penumbra's corporate governance and executive compensation practices, which are relevant to understanding the company's approach within the medical device industry.

Comparison to Industry Standards

• The document mentions a peer group of healthcare equipment, healthcare supplies, healthcare technology, and life sciences tools and services companies used for benchmarking executive compensation.
• Companies in the peer group are selected based on revenue and market capitalization, with revenue generally between $400 million and $2.0 billion and market capitalization generally between $1.4 billion and $22.0 billion.
• The 2023 peer group included companies such as ABIOMED, Artivion, AtriCure, CONMED, CryoLife, Glaukos, Globus Medical, Inogen, Insulet, Integer Holdings, Integra LifeSciences Holdings, iRhythm Technologies, Masimo, Merit Medical Systems, Neogen, Nevro, NuVasive, Quidel, Tandem Diabetes Care, Teladoc Health, and Varex Imaging.

Corporate Governance

Legal Proceedings

• The proxy statement mentions a settlement of litigation against Harpreet Grewal, a director nominee, related to SEC allegations from his previous role at Constant Contact.

Related Party Transactions

• Aidan Elsesser, the son of Adam Elsesser, our Chairman, Chief Executive Officer and President, is a non-executive employee of Penumbra and received employment compensation in excess of $120,000 in 2023, and we expect that such employee will receive employment compensation in excess of $120,000 in 2024.

Stakeholder Impact

• The proposals outlined in the proxy statement will impact shareholders through director elections, auditor ratification, and executive compensation decisions.
• Employees are impacted through the company's compensation policies and benefit plans.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on June 5, 2024, to address the outlined proposals.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Executive Compensation, PricewaterhouseCoopers, Stockholders, Corporate Governance, Penumbra